19:01 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Pertussis Cell culture and mouse studies suggest inhibiting Bordetella plrS could help treat whooping cough. In a rat lung epithelial cell line challenged with the rodent pathogen B. bronchiseptica, plrS knockout decreased bacterial adherence to...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Pluristem Life Systems Inc. preclinical data

In ischemic mice, PLX-1 revascularized treated limbs. Animals receiving controls did not have revascularization. PLX-1 is an adjuvant cell therapy product based on placenta expanded mesenchymal cells. Pluristem Life Systems Inc. (PLRS; FSE:PJT), Haifa, Israel...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Clinical News

Pluristem Life Systems Inc. preclinical data

In vitro, PLRS's PLX cells differentiated into dopaminergic neurons that expressed tyrosine hydroxylase and secreted neurotrophic factors including glial cell line-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor ( BDNF) and insulin-like growth factor-1 (...
07:00 , Jun 4, 2007 |  BC Week In Review  |  Company News

Pluristem Life Systems Inc., Israeli Ministry of Trade and Industry gene/cell therapy news

PLRS's Pluristem Ltd. subsidiary received an $830,000 grant from the ministry to develop the company's placental expanded mesenchymal stem (PLX) cell therapeutics. PLRS's lead product in the program is PLX-1, an alternative to bone...
08:00 , Feb 26, 2007 |  BC Week In Review  |  Company News

Pluristem Life Systems Inc., Stem Cell Innovations deal

SCLL received rights to market PLRS's PLX-1 and 3-D PluriX bioreactor in Asia, excluding Japan. PLX-1 is an adjuvant cell therapy based on placenta-expanded mesenchymal cells. PLX-1 is currently in preclinical studies as an alternative...
08:00 , Jan 22, 2007 |  BC Week In Review  |  Company News

Pluristem Life Systems Inc. management update

Pluristem Life Systems Inc. (PLRS), Haifa, Israel   Business: Gene/Cell therapy   Hired: William Prather as SVP of corporate development, formerly SVP of finance and business development at Boston Biomedica Inc.   ...
08:00 , Nov 6, 2006 |  BC Week In Review  |  Company News

Pluristem Life Systems Inc. management update

Pluristem Life Systems Inc. (PLRS), Haifa, Israel   Business: Gene/Cell therapy   Hired: Yaky Yanay as CFO, formerly CFO at Elbit Vision System Ltd.; he replaces Yossi Keret, who departed   ...
00:52 , Nov 2, 2006 |  BC Extra  |  Company News

Pluristem names Yanay CFO

Stem cell company PLRS hired Yaky Yanay as CFO. Previously, Yanay was CFO at Elbit Vision System (EVSN). He replaces Yossi Keret, who left to pursue other interests. On Wednesday, PLRS was down $0.0018 to...
07:00 , Oct 23, 2006 |  BC Week In Review  |  Clinical News

Pluristem Life Systems Inc. preclinical data

Researchers showed that injection of PLX-1 in combination with human umbilical cord blood-derived CD34 cells into immune-deficient mice increased the cell engraftment by up to 5-fold compared to mice injected with CD34 alone. PLX-1 is...
07:00 , Jul 10, 2006 |  BC Week In Review  |  Clinical News

Pluristem Life Systems Inc. preclinical data

In immune-deficient (NOD/SCID) mice, transplantation of umbilical cord blood (UCB)-derived hematopoeitic stem cells in combination with PLX-1 led to 2-4 times more engrafted cells when compared to transplants without PLX-1. Pluristem Life Systems Inc. (PLRS),...